President Donald Trump has been vocal about his plans to reform the American healthcare system, and now is the time for action. With the 2026 midterms looming and the focus shifting towards electoral strategy, the window for legislative change is closing rapidly. This summer will be crucial in determining whether the administration can turn promises into policies that benefit the American people.
The Trump administration, led by Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary, has outlined three key priorities in healthcare: reducing drug prices, addressing chronic diseases, and harnessing the power of generative AI. Achieving success in these areas could save lives and cut down on healthcare costs significantly.
One of the administration’s primary goals is to lower prescription drug prices, as Americans currently pay much more than citizens in other developed nations. President Trump has criticized the lack of price negotiation in the Medicare system and has signed an executive order aimed at implementing Most-Favored-Nation Prescription Drug Pricing. This order directs HHS to set price targets aligned with other developed nations and threatens additional measures if progress is not made by pharmaceutical companies. However, without congressional action, the administration’s ability to enforce lower prices remains limited.
Another pressing issue in American healthcare is the rise of obesity and chronic diseases due to the consumption of ultra-processed foods. The administration has highlighted the need for reforms in food quality and health, including front-of-package labeling, taxation on unhealthy foods, and regulation of food composition. Implementing these policies could make a significant impact on public health, but they are likely to face opposition from the food industry.
The Trump administration has also expressed a commitment to using generative AI in healthcare to improve patient outcomes and reduce costs. By leveraging AI technology, patients could receive real-time data analysis, personalized treatment plans, and improved diagnoses. However, the successful integration of AI tools into clinical practice will require investment in innovation, modernization of regulations, and a shift towards a patient-centered approach.
As the administration faces these healthcare challenges, it is essential to focus on clear goals, define success metrics, and refuse to accept failure. Grading the administration on its ability to lower drug prices, improve food quality, and integrate generative AI into healthcare will be critical in evaluating its performance. With time running out before the next election cycle, the time for action is now to deliver on these promises and make meaningful changes in American healthcare.
